HAMBURG (Thomson Financial) - German biotech company Evotec AG said it won
approval from the Securities and Exchange Commission for its shares to be listed
in the US, meeting a precondition for the planned takeover of US peer Renovis
Inc.
The SEC's go-ahead enables Evotec to call for a shareholder vote on the
acquisition, to be held at an extraordinary general meeting on May 1, the
company said in a statement.
Evotec in September said it plans to acquire Renovis for about 151.8 mln usd
in shares to focus on treatments of neurological and inflammatory diseases, and
that the combined company will apply for a Nasdaq listing.
Renovis' board or directors is backing the transaction, Ecotec said.
ludwig.burger@thomson.com
lb/rfw
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|